Steven A. Navarro

Steven also represents issuers in initial and subsequent public offerings; and issuers, as well as strategic and financial investors, in the private placement of the securities of publicly and privately held corporations. He is the former New York office practice leader for corporate and business transactions, and a former co-leader of the firm’s mergers and acquisitions practice. He is also listed as a 2013-16 Legal Media Group Life Sciences Transactional “Life Sciences Star.”

Energy and Natural Resources

• BP in the $220 million acquisition of nine gigawatts of solar development projects from 7x Energy
  BP in its $1.1 billion formation of a strategic partnership with Equinor to develop offshore wind projects in the United States. This includes the development of at least four major projects within existing offshore wind leases on the US East coast and jointly pursuing further opportunities for offshore wind in the United States
• BHP Billiton (ASX), an Australian natural resource company, in its $15.1 billion acquisition of Petrohawk Energy Corp. (NYSE), an owner of shale assets (the 8th largest deal of 2011 according to Corporate Control Alert).
• ABB Grain (ASX) on US securities matters relation to its $1.6 billion acquisition by Viterra (TSX).
• InterEnergy Partners LP, a private equity fund, in the acquisition and equity arrangements of a 120MW power plant in South America.
• InterEnergy Partners in the acquisition and equity arrangements of a non-control equity interest in a portfolio of power plants in South America of approximately 625MW and in the acquisition and equity arrangements in a non-control investment in a 300MW power plant in South America.
• a private equity fund in the acquisition and equity arrangements of a power distribution company in South America.
• private equity fund in investment in South American and Caribbean basin power generation business.

Life Sciences

• MEI Pharma, Inc., a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, in its proposed merger agreement with Infinity Pharmaceuticals, a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate
• NBE-Therapeutics (Switzerland), a clinical-stage Swiss-based biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies derived from its immune stimulatory iADC platform, in its $1.4 billion sale to Boehringer Ingelheim
• New State Capital Partners in its equity investment in Klein Hersh International, an executive search and consulting firm in the healthcare and life sciences industries
• Acerta Pharma in its $4 billion sale of a majority stake to AstraZeneca.
• Anterios to its in its $90 million sale to Allergan.
• OncoEthix in its $110 million sale to Merck with additional milestone payments of up to $265 million contingent upon certain clinical and regulatory events being achieved.
• New State Capital Partners in the acquisition of United Medical Systems.
• a Japanese pharmaceutical company in its acquisition of a development stage vaccine company for up to $250m.
• Marshall Edwards, Inc. (Nasdaq), an oncology focused company, in its acquisition of the isoflavone portfolio of Novogen Ltd. (ASX, Nasdaq) in exchange for convertible preferred stock.
• MEI Pharma in its acquisition of various compounds from S*Bio PTE LTD. for a combination of common stock and future cash payments.
• MEI Pharma in various PIPE and registered direct offerings.
• Chelsea Therapeutics in an "at-the-market" program.
• H Lundbeck A/S in the acquisition of Ovation Pharmaceuticals, a developer of CNS drugs (2009 Buyouts Magazine Deal of the Year).
• Chiesi Farmaceutici S.p.A. in its controlling investment in Cornerstone Therapeutics (Nasdaq), a maker of respiratory medicines.
• Chiesi in its 13e-3 take private of Cornerstone.
• Chelsea Therapeutics in its sale to Lundbeck for upfront cash of $6.44 per share plus a a CVR of up to $1.50 for total potential consideration of $658 million.

Manufacturing

• New State Capital Partners and its portfolio company, NWN Carousel, in the sale of NWN Carousel, a cloud communications service provider, empowers North America's largest public and private sector organizations with flexible, hybrid and intelligent workplace solutions, to American Securities LLC
• New State Capital Partners and United Medical Systems Inc. in the sale of UMS to Access & Integrated Practice Holdings, a portfolio company of MGG Investment Group
• New State Capital Partners in its majority equity investment in Wilmington Paper Corp., a value-added services provider in the recovered paper-based fiber space
• New State Capital Partners in its acquisition of AVEX, a provider of sales and maintenance for the Daher TBM turboprop aircraft in North America
• Owens Corning in a $1.8 billion worldwide manufacturing joint venture and related equity transactions.
• Owens Corning in the $800m acquisition of a worldwide specialty glass yarns business.
• Ferro Corporation in the acquisition of a European and Asian ceramics business structured as an asset swap.
• Sun Capital, a private equity fund, in the sale of Sonneborn, Inc., a global specialty petro chemical manufacturer.
• Owens Corning in the joint venture of its cultured stone business.
• Sekesui in a US based manufacturing joint venture and related equity transaction.

Retail

• Sun Capital Partners in its $1.2 billion acquisition of ShopKo Stores, a publicly traded Midwestern based retailer and related equity investments by co-investors.
• ShopKo Stores in its $3 billion combination with Pamida Inc.
• financial participants in a $3 billion private equity acquisition of BJ's Wholesale Club.
• Sun Capital Partners in its acquisition of Friendly's Ice Cream (Nasdaq).